Suchergebnisse
10
Alles
Such-Filter
Organisationen
23andMe, Inc.
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
26. März 2025 18:57 ET
|
23andMe, Inc.
SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has...
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
23. März 2025 23:08 ET
|
23andMe, Inc.
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures...
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
21. März 2025 07:30 ET
|
23andMe, Inc.
SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human...
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
03. März 2025 16:35 ET
|
23andMe, Inc.
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a...
23andMe Launches New Genetic Report on Osteoporosis
31. Januar 2025 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human...
23andMe Special Committee Announces Exploration of Strategic Alternatives
28. Januar 2025 17:25 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
28. Januar 2025 17:15 ET
|
23andMe, Inc.
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
08. Januar 2025 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
20. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
12. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter...